GangaGen, Inc. To Present New Preclinical Data On P128 At American Society of Microbiology Microbe 2017
-Three posters on P128 selected for presentation at leading microbial sciences forum
- P128’s potential as a novel anti-Staphylococcal protein for the treatment of serious infections such as MRSA investigated
UNITED STATES, 22 MAY 2017 – GangaGen Inc., a biotechnology company developing novel therapeutic proteins for infectious diseases, announces the presentation of new data on P128, its proprietary phage-derived ectolysin that targets Staphylococcus bacteria, at the upcoming American Society for Microbiology 2017 forum taking place on 1-5 June 2017 in New Orleans, Louisiana.
GangaGen will present three posters at the event. The data to be presented investigate the synergistic effect of P128 in combination with low doses of antibiotics against drug-resistant strains of Staphylococcus aureus. Additional data investigating the pharmacokinetics and efficacy of P128 against systemic methicillin resistant Staphylococcus aureus (MRSA) and data from a novel preclinical model evaluating the efficacy following systemic administration of P128 in the treatment of bacteremia and renal abscesses will also be presented.
Infections caused by MRSA and coagulase-negative Staphylococci (CoNS) can be expensive to treat and have serious clinical outcomes, including death. Global initiatives support the development of innovative therapies to treat these infections and reduce the burden of antibiotic resistance. GangaGen is currently investigating the potential of P128 to meet this critical need. Recently announced data on P128 have demonstrated its potential as a novel therapy which can rapidly kill these dangerous bacteria, even in a quiescent state, without contributing to resistance or disrupting beneficial bacterial flora.
Details of the poster presentations are as follows:
Title: Reversal of Drug Resistant Phenotype of Staphylococcus Clinical Strains by Synergistic Action of P128 and Antibiotics
Session: Session 050 - AAID11 - New Antimicrobial Agents: New Antibacterial Approaches
Date and time: 2 June 2017, 12:45-14:45 EST
Poster Location: Exhibit Hall D, Exhibit and Poster Hall
Title: Preclinical Studies of Anti-Staphylococcal Ectolysin P128 for Potential Systemic Hypersensitivity and Evaluation of Efficacy in Staphylococcus aureus Bacteremia with Renal Abscesses in Rats
Session: Session 050 - AAID11 - New Antimicrobial Agents: New Antibacterial Approaches
Date and time: 2 June 2017, 12:45-14:45 EST
Poster Location: Exhibit Hall D, Exhibit and Poster Hall
Title: Pharmacokinetics and Efficacy of P128 in a Mouse Model of Systemic Methicillin Resistant Staphylococcus aureus (MRSA) Infection
Session: Session 050 - AAID11 - New Antimicrobial Agents: New Antibacterial Approaches
Date and time: 2 June 2017, 12:45-14:45 EST
Poster Location: Exhibit Hall D, Exhibit and Poster Hall
Copies of the posters containing the relevant information will be made available on the GangaGen website following the presentations.
Media contact
Jamie Maarten / Emma Thompson
Spurwing Communications
Tel: +65 6340 7287
Email: gangagen@spurwingcomms.com
About P128
P128 is an ectolysin, a proprietary phage-derived protein with a novel mechanism of action that allows it to rapidly and specifically kill Staphylococcus bacteria, including drug resistant strains such as methicillin-resistant Staphylococcus aureus
(MRSA) and coagulase-negative Staphylococci (CoNS). Due to its novel mode of action, no naturally occurring resistance to P128 has been detected. To date, P128 has been shown in vitro to effectively kill over 120 strains of S. aureus, representing more than 3,000 isolates, and has demonstrated a similar level of efficacy against CoNS, which are associated
with serious device-associated infections in hospitals. P128 is also active against Staphylococci in biofilms. The unique mechanism of P128 allows it to kill the bacterium without needing to enter the cell, allowing it to act rapidly and to kill bacteria present in biofilms. P128’s specificity allows it to kill Staphylococcus bacteria without disrupting beneficial bacterial flora.
About GangaGen, Inc.
GangaGen, Inc. is a biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. GangaGen is based in the United States with research facilities in Bangalore, India. For more information, please visit www.gangagen.com.
- P128’s potential as a novel anti-Staphylococcal protein for the treatment of serious infections such as MRSA investigated
UNITED STATES, 22 MAY 2017 – GangaGen Inc., a biotechnology company developing novel therapeutic proteins for infectious diseases, announces the presentation of new data on P128, its proprietary phage-derived ectolysin that targets Staphylococcus bacteria, at the upcoming American Society for Microbiology 2017 forum taking place on 1-5 June 2017 in New Orleans, Louisiana.
GangaGen will present three posters at the event. The data to be presented investigate the synergistic effect of P128 in combination with low doses of antibiotics against drug-resistant strains of Staphylococcus aureus. Additional data investigating the pharmacokinetics and efficacy of P128 against systemic methicillin resistant Staphylococcus aureus (MRSA) and data from a novel preclinical model evaluating the efficacy following systemic administration of P128 in the treatment of bacteremia and renal abscesses will also be presented.
Infections caused by MRSA and coagulase-negative Staphylococci (CoNS) can be expensive to treat and have serious clinical outcomes, including death. Global initiatives support the development of innovative therapies to treat these infections and reduce the burden of antibiotic resistance. GangaGen is currently investigating the potential of P128 to meet this critical need. Recently announced data on P128 have demonstrated its potential as a novel therapy which can rapidly kill these dangerous bacteria, even in a quiescent state, without contributing to resistance or disrupting beneficial bacterial flora.
Details of the poster presentations are as follows:
Title: Reversal of Drug Resistant Phenotype of Staphylococcus Clinical Strains by Synergistic Action of P128 and Antibiotics
Session: Session 050 - AAID11 - New Antimicrobial Agents: New Antibacterial Approaches
Date and time: 2 June 2017, 12:45-14:45 EST
Poster Location: Exhibit Hall D, Exhibit and Poster Hall
Title: Preclinical Studies of Anti-Staphylococcal Ectolysin P128 for Potential Systemic Hypersensitivity and Evaluation of Efficacy in Staphylococcus aureus Bacteremia with Renal Abscesses in Rats
Session: Session 050 - AAID11 - New Antimicrobial Agents: New Antibacterial Approaches
Date and time: 2 June 2017, 12:45-14:45 EST
Poster Location: Exhibit Hall D, Exhibit and Poster Hall
Title: Pharmacokinetics and Efficacy of P128 in a Mouse Model of Systemic Methicillin Resistant Staphylococcus aureus (MRSA) Infection
Session: Session 050 - AAID11 - New Antimicrobial Agents: New Antibacterial Approaches
Date and time: 2 June 2017, 12:45-14:45 EST
Poster Location: Exhibit Hall D, Exhibit and Poster Hall
Copies of the posters containing the relevant information will be made available on the GangaGen website following the presentations.
Media contact
Jamie Maarten / Emma Thompson
Spurwing Communications
Tel: +65 6340 7287
Email: gangagen@spurwingcomms.com
About P128
P128 is an ectolysin, a proprietary phage-derived protein with a novel mechanism of action that allows it to rapidly and specifically kill Staphylococcus bacteria, including drug resistant strains such as methicillin-resistant Staphylococcus aureus
(MRSA) and coagulase-negative Staphylococci (CoNS). Due to its novel mode of action, no naturally occurring resistance to P128 has been detected. To date, P128 has been shown in vitro to effectively kill over 120 strains of S. aureus, representing more than 3,000 isolates, and has demonstrated a similar level of efficacy against CoNS, which are associated
with serious device-associated infections in hospitals. P128 is also active against Staphylococci in biofilms. The unique mechanism of P128 allows it to kill the bacterium without needing to enter the cell, allowing it to act rapidly and to kill bacteria present in biofilms. P128’s specificity allows it to kill Staphylococcus bacteria without disrupting beneficial bacterial flora.
About GangaGen, Inc.
GangaGen, Inc. is a biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. GangaGen is based in the United States with research facilities in Bangalore, India. For more information, please visit www.gangagen.com.